Showing results (681-690 of 706) with videos related to
Sort By:
Pageof 71
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast CancerErica L Mayer, Yue Ren, Nikhil Wagle, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.JAMA Oncology|March 9, 2023
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical TrialTufia C Haddad, Vera J Suman, Antonino B D'Assoro, et al.Journal of the National Cancer Institute|December 7, 2023
Taxanes for the treatment of breast cancer during pregnancy: an international cohort studyAna S Ferrigno Guajardo, Bryan F Vaca-Cartagena, Erica L Mayer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.The Lancet. Oncology|July 13, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trialNicholas C Turner, Erica L Mayer, Yeon Hee Park, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030H A Parsons, T Blewett, X Chu, et al.Medrxiv : the Preprint Server for Health Sciences|March 22, 2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030Heather A Parsons, Timothy Blewett, Xiangying Chu, et al.Cancer|January 18, 2024
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131Karen L Smith, Fengmin Zhao, Ingrid A Mayer, et al.JAMA Oncology|August 21, 2025
Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer: Secondary Analysis of the Breast Cancer Weight Loss (BWEL) TrialJennifer A Ligibel, Karla V Ballman, Linda McCall, et al.Pageof 71